<unk> , sold under the brand name Steglatro, is a medication for the treatment of type 2 diabetes. The most common side effects include fungal infections of the vagina and other infections of the female reproductive system.<unk>  is a sodium/glucose cotransporter 2 (SGLT2) inhibitor and is in the class of drugs known as gliflozins. In the United States, it was approved by the Food and Drug Administration for use as a monotherapy and as a fixed dose combination with either sitagliptin or with metformin. In the European Union, it was approved in March 2018, for use as a monotherapy or combination therapy. In September 2020, The New England Journal of Medicine reported that<unk>  was shown to be essentially non-inferior to placebo. A combination with metformin is marketed as Segluromet and a combination with sitagliptin is marketed as Steglujan.
Ertugliflozin
Ipragliflozin
Linagliptin
Liraglutide
Exenatide
Vildagliptin
Saxagliptin
Sitagliptin